GIACOMELLI, ROBERTO
 Distribuzione geografica
Continente #
AS - Asia 15.427
NA - Nord America 9.480
EU - Europa 3.976
SA - Sud America 1.813
AF - Africa 222
Continente sconosciuto - Info sul continente non disponibili 166
OC - Oceania 55
AN - Antartide 1
Totale 31.140
Nazione #
US - Stati Uniti d'America 9.061
SG - Singapore 8.489
CN - Cina 2.709
HK - Hong Kong 2.222
IT - Italia 1.848
BR - Brasile 1.356
VN - Vietnam 768
GB - Regno Unito 649
FR - Francia 541
BD - Bangladesh 413
DE - Germania 261
IN - India 223
CA - Canada 222
AR - Argentina 182
NL - Olanda 120
ID - Indonesia 117
MX - Messico 102
EC - Ecuador 83
ZA - Sudafrica 80
TR - Turchia 77
UA - Ucraina 74
JP - Giappone 73
ES - Italia 61
CO - Colombia 60
IQ - Iraq 56
RU - Federazione Russa 53
AU - Australia 50
PL - Polonia 45
CL - Cile 39
FI - Finlandia 38
PY - Paraguay 36
SA - Arabia Saudita 34
CZ - Repubblica Ceca 33
MA - Marocco 32
AT - Austria 31
SE - Svezia 29
PE - Perù 26
PK - Pakistan 25
JM - Giamaica 24
EG - Egitto 23
MD - Moldavia 22
PT - Portogallo 22
TN - Tunisia 22
RO - Romania 20
UZ - Uzbekistan 20
PH - Filippine 19
VE - Venezuela 19
CR - Costa Rica 17
IL - Israele 14
JO - Giordania 14
NP - Nepal 14
KE - Kenya 13
KZ - Kazakistan 13
LT - Lituania 13
IR - Iran 12
OM - Oman 12
DK - Danimarca 11
AE - Emirati Arabi Uniti 10
AL - Albania 10
BG - Bulgaria 10
HN - Honduras 10
IE - Irlanda 10
LB - Libano 10
DZ - Algeria 9
GT - Guatemala 9
AZ - Azerbaigian 8
CH - Svizzera 8
DO - Repubblica Dominicana 8
ET - Etiopia 8
KR - Corea 8
TH - Thailandia 8
BE - Belgio 7
GR - Grecia 7
MY - Malesia 7
SK - Slovacchia (Repubblica Slovacca) 7
SV - El Salvador 7
UY - Uruguay 7
EE - Estonia 6
KW - Kuwait 6
RS - Serbia 6
BA - Bosnia-Erzegovina 5
GH - Ghana 5
LU - Lussemburgo 5
LV - Lettonia 5
NI - Nicaragua 5
SN - Senegal 5
BO - Bolivia 4
CG - Congo 4
PA - Panama 4
SI - Slovenia 4
TW - Taiwan 4
AF - Afghanistan, Repubblica islamica di 3
BH - Bahrain 3
CY - Cipro 3
HU - Ungheria 3
IS - Islanda 3
KG - Kirghizistan 3
LK - Sri Lanka 3
PS - Palestinian Territory 3
QA - Qatar 3
Totale 30.905
Città #
San Jose 2.942
Hong Kong 2.197
Ashburn 1.892
Singapore 1.716
Rome 1.287
Hefei 1.104
Council Bluffs 728
Boardman 618
Columbus 575
London 527
Beijing 481
Lauterbourg 473
Shanghai 359
Dallas 347
Ho Chi Minh City 295
New York 159
Santa Clara 151
Hanoi 150
Los Angeles 137
São Paulo 113
Pune 97
San Francisco 94
Amsterdam 78
Toronto 72
Munich 61
Washington 53
Seattle 52
Tokyo 52
Mexico City 47
Naples 44
Milan 42
Haiphong 37
Warsaw 37
Brooklyn 36
Frankfurt am Main 36
Montreal 36
Da Nang 34
Rio de Janeiro 34
Brasília 33
Las Vegas 33
Buffalo 31
Baghdad 30
Ankara 29
Chicago 29
Johannesburg 28
Guayaquil 27
Quito 24
Stockholm 24
Atlanta 23
Turku 23
Bari 22
Biên Hòa 22
Guangzhou 22
Nuremberg 21
Porto Alegre 21
Curitiba 20
Thái Bình 20
West Jordan 20
Boston 19
Brno 19
Chennai 19
Phoenix 19
Buenos Aires 18
Cape Town 18
Hải Dương 18
Jinan 18
Manchester 18
Belo Horizonte 17
Campinas 17
Sydney 17
Vienna 17
Guarulhos 16
Hangzhou 16
Kingston 16
Lima 16
Tashkent 16
Charlotte 15
Jakarta 15
San José 15
Changsha 14
Riyadh 14
Turin 14
Can Tho 13
Dhaka 13
Helsinki 13
Madrid 13
Manaus 13
Medellín 13
Melbourne 13
Amman 12
Hortolândia 12
Lấp Vò 12
Ottawa 12
Paris 12
Salvador 12
Tunis 12
Bengaluru 11
Bogotá 11
Bologna 11
Cairo 11
Totale 18.315
Nome #
Fibroblast expression of CD248 may contribute to exacerbate microvascular damage during systemic sclerosis 272
------- 243
Adipocytokines in Rheumatoid Arthritis: The Hidden Link between Inflammation and Cardiometabolic Comorbidities 238
Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments 235
Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study 222
Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis 222
A comprehensive review on adult onset Still's disease 217
AB0550 PHENOTYPE OF BIOPSY-PROVEN PATIENTS WITH PRIMARY SJÖGREN SYNDROME LACKING RO AUTOANTIBODIES: HIGH FREQUENCY OF DRYNESS SYMPTOMS WITH LOW SYSTEMIC ACTIVITY (BIG DATA SJÖGREN PROJECT) 210
Efficacy and safety of imatinib mesylate in systemic sclerosis. A systematic review and meta-analysis 206
Cardiometabolic multimorbidity may identify a more severe subset of rheumatoid arthritis, results from a “real-life” study 205
Adipose stromal vascular fraction and regenerative therapy in SSc: Response to the article by Magalon et al 202
Cytokine profile, ferritin, and multi-visceral involvement characterise macrophage activation syndrome during adult-onset Still's disease 198
Clinical characteristics of obese patients with adult-onset Still's disease. Data from a large multicentre cohort 196
Aberrant expression of IL-22RA1 on hematopoietic cells as immunologically signature of primary sjogren’s syndrome and sjogren-associated non-hodgkin lymphomas 195
A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis 194
AB0458 A PHASE II RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF OF CONCEPT STUDY OF ORAL SELETALISIB IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME (PSS) 192
Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients' subgroups 184
Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies 179
Clinical and laboratory features associated with macrophage activation syndrome in Still’s disease: data from the international AIDA Network Still’s Disease Registry 177
A3.1 Pathogenic role of IL-17 producing double negative (DN) T cells in primary sjögren’s syndrome 176
Bosentan effect on echocardiographic systolic pulmonary arterial pressure in systemic sclerosis-related pulmonary hypertension: a systematic review and metanalysis 171
Clinical correlates of a subset of anti-fibroblast antibodies in systemic sclerosis 169
Adult-onset Still's disease with elderly onset: results from a multicentre study 167
2-Arachidonoylglycerol Reduces the Production of Interferon-Gamma in T Lymphocytes from Patients with Systemic Lupus Erythematosus 167
2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19 156
Clinical and subclinical atherosclerosis in patients with systemic sclerosis: an observational, multicentre study of GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) 143
ASSESSING PRO-INFLAMMATORY PROPERTIES OF H-FERRITIN BY EX VIVO AND IN VITRO OBSERVATIONS 127
Duration of clinical remission and low disease activity impacts on quality of life and its domains in psoriatic arthritis patients: results from an Italian multicentre study 124
The clinical assessment of lung involvement in patients with Still’s disease, results from the multicentre international AIDA Network Still’s Disease Registry 123
Derivation and validation of four patient clusters in Still’s disease, results from GIRRCS AOSD-study group and AIDA Network Still Disease Registry 120
A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis. 120
Association Between Minor Salivary Gland Biopsy During Sjӧgren's Syndrome and Serologic Biomarkers: A Systematic Review and Meta-Analysis 120
The measurement of fibromyalgia severity: converting scores between the FIQR, the PSD and the FASmod 119
International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management. 118
Impact of smoking habit on adult-onset Still's disease prognosis, findings from a multicentre observational study 118
Cardiovascular Risk Prediction in Ankylosing Spondylitis: From Traditional Scores to Machine Learning Assessment 117
). IL-6 e TGF-b1 nel siero e nei sovranatanti di cellule mononucleate in pazienti con sclerosi sistemica (SSC). 114
Recent advances and evolving concepts in Still's disease 111
Aberrant cytokine expression and severity of the infiltrates are reverted by rituximab therapy in salivary glands of patients with Sjogren’s syndrome 111
Addressing the clinical unmet needs in primary Sjögren's Syndrome through the sharing, harmonization and federated analysis of 21 European cohorts 111
Activation antigens and adhesion molecules expression on Vd1+ T cells in systemic sclerosis (SSc) 109
Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets? 108
Correction to: Impact of smoking habit on adult-onset Still's disease prognosis, findings from a multicentre observational study 107
Cytokine storm syndrome in severe COVID-19 107
EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease 105
EVIDENCE FOR REDUCED ANGIOGENESIS IN BONE MARROW (BM) IN SYSTEMIC SCLEROSIS (SSC) 105
Association between clinical, histopathological and molecular features in primary Sjogren's Syndrome: a retrospective study 104
Development and implementation of the AIDA International Registry for patients with Behçet's disease 103
Incidence, prevalence and mortality of systemic sclerosis in Italy: a nationwide population-based study using administrative health data 103
The Relationship Between Metabolic Syndrome and Pain Catastrophizing in Psoriatic Arthritis 100
Clinical features and prognosis of COVID-19 in people with spinal cord injury: a case–control study 99
How the different systemic organ involvements are overlapped in patients with primary Sjogren syndrome: analysis using a mathematical model 99
Pain catastrophizing negatively impacts drug retention rate in patients with Psoriatic Arthritis and axial Spondyloarthritis: results from a 2-years perspective multicenter GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica) study 98
Benefits of anakinra versus TNF inhibitors in rheumatoid arthritis and type 2 diabetes: long-term findings from participants furtherly followed-up in the TRACK study, a multicentre, open-label, randomised, controlled trial 98
Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: A new potential target for antifibrotic therapy 97
The specialized pro-resolving lipid mediator Protectin D1 affects macrophages differentiation and activity in Adult-onset Still's disease and COVID-19, two hyperinflammatory diseases sharing similar transcriptomic profiles 93
Cardiovascular disease in primary sjögren’s syndrome 92
The Effect of Ketogenic Diet on Inflammatory Arthritis and Cardiovascular Health in Rheumatic Conditions: A Mini Review 92
Polyclonal B lymphocyte activation in progressive systemic sclerosis. 91
SARS-CoV-2 infection in patients with primary Sjögren syndrome: characterization and outcomes of 51 patients 91
Macrophage activation syndrome in patients affected by adult-onset still disease: Analysis of survival rates and predictive factors in the Gruppo Italiano di Ricerca in reumatologia clinica e sperimentale cohort 90
The economic burden of fibromyalgia: A systematic literature review 89
Association between Patient Acceptable Symptom State and disease activity in psoriatic arthritis is disrupted by confounders, including comorbid fibromyalgia 88
Interstitial Lung Disease and Pulmonary Damage in Primary Sjögren's Syndrome: A Systematic Review and Meta-Analysis 85
Development and Implementation of the AIDA International Registry for Patients With VEXAS Syndrome 84
Mortality in tocilizumab-treated patients with COVID-19: a systematic review and meta-analysis 83
Clinical targeted treatment in Sjogren's disease: A systematic literature review for an evidence-based medicine approach 81
Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers 79
Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis 78
Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases 78
Mediterranean diet and Psoriatic Arthritis activity: a multicenter cross-sectional study 77
EULAR Textbook on Rheumatic Diseases – Third Edition (2018) 77
Correction: Clinical and laboratory features associated with macrophage activation syndrome in Still’s disease: data from the international AIDA Network Still’s Disease Registry 76
Primary versus systemic-sclerosis-associated Raynaud's phenomenon: relationship with clinical and environmental factors 76
The evaluation of type I interferon score in dermatomyositis, a systematic review and a meta-analysis 75
Association Between the Use of Oral Contraceptives and the Development of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis 74
SCLERODERMA FIBROBLASTS SUPPRESS ANGIOGENESIS VIA TGF-beta/CAVEOLIN-DEPENDENT SECRETION OF PIGMENTED EPITHELIUM DERIVED FACTOR: TGF-beta RECEPTOR INHIBITORS AS A NOVEL THERAPEUTIC TARGET FOR THE TREATMENT OF SCLERODERMA 74
A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome 74
Multicenter Validation of the DETAIL Questionnaire for the Screening of Spondyloarthritis in Patients With Inflammatory Bowel Diseases 73
The Vessels Contribute to Fibrosis in Systemic Sclerosis 73
Novel biomarker for pulmonary vascular disease in systemic sclerosis patients 72
Pro-inflammatory properties of H-ferritin on human macrophages, ex vivo and in vitro observations 72
The assessment of the drug retention rate of secukinumab in patients with psoriatic arthritis in a real-life multicentre cohort 71
Vascular complications of scleroderma 71
The assessment of atlantoaxial joint involvement in patients with rheumatoid arthritis, results from an observational “real-life” study 70
Interleukin-25 Axis Is Involved in the Pathogenesis of Human Primary and Experimental Murine Sjögren's Syndrome 70
Beyond the joints, the extra-articular manifestations in rheumatoid arthritis 70
Unenhanced Cardiac Magnetic Resonance may improve detection and prognostication of an occult heart involvement in asymptomatic patients with systemic sclerosis 70
Where are we going in the management of interstitial lung disease in patients with systemic sclerosis? 69
Maladaptive Autophagy in the Pathogenesis of Autoimmune Epithelitis in Sjögren's Syndrome 69
Systemic Sjogren presenting without sicca syndrome: characterization of 240 patients according to the new 2017 ACR/EULAR Classification Criteria 68
Increased cardiovascular events and subclinical atherosclerosis in rheumatoid arthritis patients: 1 year prospective single centre study 68
New biologic (Ab-IPL-IL-17) for IL-17-mediated diseases: identification of the bioactive sequence (nIL-17) for IL-17A/F function 67
Expanding the spectrum of the hyperferritinemic syndrome, from pathogenic mechanisms to clinical observations, and therapeutic implications 66
Interstitial lung disease in systemic sclerosis: Pathophysiology and therapy 66
Long-term retention rate of anakinra in adult onset Still’s disease and predictive factors for treatment response 65
PTP4A1 promotes TGFβ signaling and fibrosis in systemic sclerosis 65
Systemic sclerosis interstitial lung disease: unmet needs and potential solutions 64
Factors influencing the patient evaluation of injection experience with the SmartJect autoinjector in rheumatoid arthritis. 64
The kaleidoscope of neurological manifestations in primary Sjögren's syndrome 64
Totale 11.735
Categoria #
all - tutte 246.777
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 246.777


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022648 0 5 29 4 7 2 4 4 55 29 19 490
2022/2023318 5 15 11 28 73 13 6 7 10 11 130 9
2023/20241.786 60 216 61 144 198 839 32 85 17 51 40 43
2024/202510.867 230 179 617 113 109 364 242 64 1.422 1.088 3.012 3.427
2025/202616.151 1.556 496 1.216 2.243 456 944 4.069 1.311 1.231 1.258 801 570
2026/20271.370 183 1.187 0 0 0 0 0 0 0 0 0 0
Totale 31.140